Research progress and current status of immunotherapy and ablation therapy in hepatocellular carcinoma
10.3760/cma.j.cn115355-20221214-00789
- VernacularTitle:免疫治疗与消融治疗在肝细胞癌中的研究进展与现状
- Author:
Qian MA
1
;
Lele CHANG
;
Ji TAO
Author Information
1. 哈尔滨医科大学附属肿瘤医院消化内科二病房，哈尔滨 150000
- Keywords:
Carcinoma, hepatocellular;
Immune checkpoint inhibitors;
Ablation therapy;
Research progress
- From:
Cancer Research and Clinic
2023;35(12):947-950
- CountryChina
- Language:Chinese
-
Abstract:
As solid tumor therapy enters the immunological era, hepatocellular carcinoma immunotherapy starts in advanced second-line, from second-line to first-line, from single agent to combination, and from late stage to early stage. Radiofrequency ablation and microwave ablation have become first-line therapies for local ablation of early hepatocellular carcinoma, and emerging ablation techniques are also being developed in clinical trials and/or cell/animal studies. In the exploration of treatment regimens of hepatocellular carcinoma, the limitation of single therapy has become increasingly obvious, and the exploration of combination therapy has begun. This article reviews the research progress of immunotherapy and ablation therapy in hepatocellular carcinoma, aiming to provide new directions and insights for clinical treatment of hepatocellular carcinoma.
